The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

The FDA has approved Cabenuva, a long-acting HIV treatment from ViiV and Johnson & Johnson that keeps the virus at bay with a monthly injection instead of daily pill regimen. It follows a surprise ...

The company is also developing a vaccine against a bacteria that causes urinary tract infections, bloodstream infections, and pneumonias, and testing approved drugs Cabenuva and Edurant in ...

HIV therapy protects the immune system by controlling the virus and preventing disease progression. This article takes a ...

The list includes dengue fever, chikungunya, leptospirosis and Valley fever, says University of Washington professor Peter ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.